May 19, 2018 (Medical News Today) This study was published in the Journal of Experimental Medicine. It discovered that when cholesterol levels are decreased, cancer fighting immunotherapy is more effective. …
New Study Finds that Lowering Cholesterol Improves Immunotherapy Read More
April 11, 2018 (HealthDay News) One-year overall survival of 61 percent for gemcitabine and cisplatin plus ipilimumab Gemcitabine and cisplatin (GC) plus ipilimumab is associated with a 69 percent objective …
Combo of Chemo & Immunotherapy Determined Feasible in Metastatic Bladder Cancer Read More
In January, ASCO published its 13th annual report in Clinical Cancer Advances 2018, and named chimeric antigen receptor (CAR) T-cell immunotherapy as its Advance of the Year. This repost highlights …
CAR T-Cell Immunotherapy Named Clinical Advance of the Year by ASCO Read More
What’s Next for CAR T-Cell Therapy? Top issues for researchers and clinicians utilizing CAR T-cell therapy include: Shortening the manufacturing time and vein-to-vein time, scaling productivity, managing side effects, and …
CAR T-Cell Therapy HCP Guide – Future Implications for CAR T-Cell Therapy Read More